Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-Line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802)

Trial Profile

Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-Line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2009 Primary endpoint 'Time to treatment failure' has not been met.
    • 05 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top